KR102634811B1 - 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 - Google Patents

면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 Download PDF

Info

Publication number
KR102634811B1
KR102634811B1 KR1020207000802A KR20207000802A KR102634811B1 KR 102634811 B1 KR102634811 B1 KR 102634811B1 KR 1020207000802 A KR1020207000802 A KR 1020207000802A KR 20207000802 A KR20207000802 A KR 20207000802A KR 102634811 B1 KR102634811 B1 KR 102634811B1
Authority
KR
South Korea
Prior art keywords
group
polysaccharides
capsular
kda
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207000802A
Other languages
English (en)
Korean (ko)
Other versions
KR20200014921A (ko
Inventor
수브하쉬 브이. 카프레
아누프 케이. 다타
Original Assignee
인벤트프라이즈 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인벤트프라이즈 인크. filed Critical 인벤트프라이즈 인크.
Priority to KR1020247004035A priority Critical patent/KR20240018697A/ko
Priority to KR1020247004036A priority patent/KR20240018698A/ko
Publication of KR20200014921A publication Critical patent/KR20200014921A/ko
Application granted granted Critical
Publication of KR102634811B1 publication Critical patent/KR102634811B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207000802A 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 Active KR102634811B1 (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020247004035A KR20240018697A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
KR1020247004036A KR20240018698A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517905P 2017-06-10 2017-06-10
US62/517,905 2017-06-10
PCT/US2018/036868 WO2018227177A1 (en) 2017-06-10 2018-06-11 Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020247004036A Division KR20240018698A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
KR1020247004035A Division KR20240018697A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신

Publications (2)

Publication Number Publication Date
KR20200014921A KR20200014921A (ko) 2020-02-11
KR102634811B1 true KR102634811B1 (ko) 2024-02-06

Family

ID=64562792

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020207000802A Active KR102634811B1 (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
KR1020247004036A Pending KR20240018698A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
KR1020247004035A Pending KR20240018697A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247004036A Pending KR20240018698A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
KR1020247004035A Pending KR20240018697A (ko) 2017-06-10 2018-06-11 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신

Country Status (12)

Country Link
US (1) US10688170B2 (https=)
EP (1) EP3634481A4 (https=)
JP (1) JP7132954B2 (https=)
KR (3) KR102634811B1 (https=)
CN (2) CN118356485A (https=)
AU (1) AU2018280272C1 (https=)
BR (1) BR112019026192B1 (https=)
CA (1) CA3066911C (https=)
MX (2) MX2019014829A (https=)
MY (1) MY198400A (https=)
WO (1) WO2018227177A1 (https=)
ZA (1) ZA201908528B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283102A4 (en) * 2015-04-16 2018-10-03 Inventprise, LLC. Bordetella pertussis immunogenic vaccine compositions
CN108367063A (zh) * 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.
TWI725359B (zh) 2017-12-06 2021-04-21 美商默沙東藥廠 包含肺炎鏈球菌多醣-蛋白結合物之組合物及其使用方法
CA3120922A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
GEAP202415690A (en) 2018-12-19 2024-01-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2021014710A (es) * 2019-06-05 2022-01-18 Merck Sharp & Dohme Llc Un conjugado inmunogenico de polisacarido de neumococo del serotipo 35b- proteina y proceso de conjugacion para preparar el mismo.
CN110804097B (zh) * 2019-10-30 2021-02-26 云南沃森生物技术股份有限公司 一种同时制备两种单克隆抗体的方法
KR20220146451A (ko) * 2020-01-17 2022-11-01 인벤트프라이즈 엘엘씨 다가 스트렙토코커스 백신
CN111643661A (zh) * 2020-06-08 2020-09-11 王竹林 新型免疫佐剂、化合物及其应用
WO2022035816A1 (en) * 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
KR20230097160A (ko) * 2020-11-04 2023-06-30 화이자 인코포레이티드 폐렴구균 백신에 사용하기 위한 면역원성 조성물
CN113173977B (zh) * 2021-05-12 2024-03-29 江苏坤力生物制药有限责任公司 一种双功能抗原、其制备方法及应用
CN115721709A (zh) * 2021-08-27 2023-03-03 康希诺生物股份公司 一种肺炎球菌结合疫苗制备方法
GB2614916A (en) 2022-01-25 2023-07-26 Optivalent Ltd Intradermal vaccine complement
JP7759476B2 (ja) * 2022-03-18 2025-10-23 デンカ株式会社 リンカーにより連結されたカプシドタンパク質を含むウイルス様粒子
CN117643624A (zh) * 2024-01-30 2024-03-05 成都康华生物制品股份有限公司 一种双价多糖结合疫苗的制备方法及双价多糖结合疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080260773A1 (en) * 2004-12-24 2008-10-23 Giuseppe Del Giudice Saccharide Conjugate Vaccines
US20090317412A1 (en) * 2004-06-04 2009-12-24 Alexander Jeffery L Induction of an immune response against streptococcus pneumoniae polyaccharides

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360897A (en) 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5849301A (en) 1993-09-22 1998-12-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluable carbohydrates activated via organic cyanylating reagents
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US5866132A (en) 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
DE69942176D1 (de) 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
ES2275499T3 (es) 1999-03-19 2007-06-16 Glaxosmithkline Biologicals S.A. Vacuna contra streptococcus pneumoniae.
FR2806304B1 (fr) 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0130215D0 (en) 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
NZ536859A (en) 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
EP1532159A4 (en) 2002-06-20 2009-10-21 Univ Maryland Biotech Inst MALEIMIDES CLUSTERS ON SCAFFOLDING FOR PLURIVALENT PEPTIDE ASSEMBLIES
AU2003257003A1 (en) * 2002-07-30 2004-02-16 Baxter Healthcare S.A. Chimeric multivalent polysaccharide conjugate vaccines
KR101052996B1 (ko) 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
CN100423774C (zh) 2003-08-06 2008-10-08 美国政府健康及人类服务部 制备多糖-蛋白轭合物疫苗的方法
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
US20050118199A1 (en) 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2604363C (en) 2005-04-08 2015-06-16 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
NZ598367A (en) 2005-09-01 2013-10-25 Novartis Vaccines & Diagnostic Multiple vaccination including serogroup C meningococcus
PL1973564T3 (pl) 2005-12-22 2017-04-28 Glaxosmithkline Biologicals S.A. Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
AU2006336520B2 (en) 2005-12-28 2011-09-15 The Uab Research Foundation Pneumococcal serotypes
US8481054B2 (en) 2005-12-28 2013-07-09 The UAB Foundation Pneumococcal serotypes
WO2007106435A2 (en) 2006-03-10 2007-09-20 University Of California Cleavable vaccines compositions and methods of making and using the same
AU2007227504B2 (en) 2006-03-17 2013-10-31 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for preparing complex multivalent immunogenic conjugates
AR060187A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
WO2007127668A2 (en) 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2008021076A2 (en) * 2006-08-07 2008-02-21 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
PT2129693T (pt) 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
EP2170391B1 (en) * 2007-06-20 2017-01-18 Pfizer Ireland Pharmaceuticals Modified polysaccharides for conjugate vaccines
SI2167121T1 (sl) 2007-06-26 2015-12-31 Glaxosmithkline Biologicals S.A. Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
AU2009208403A1 (en) 2008-02-01 2009-08-06 Newcastle Innovation Limited Vaccine compositions
EP2108656A1 (en) 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
KR20110091546A (ko) 2008-12-18 2011-08-11 와이어쓰 엘엘씨 스트렙토코커스 뉴모니에 혈청형 19ａ 폴리사카라이드 분자량을 조절하는 방법
AU2010243285B2 (en) 2009-04-30 2013-06-06 Coley Pharmaceutical Group, Inc. Pneumococcal vaccine and uses thereof
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
BR112012005349A2 (pt) 2009-09-09 2016-03-29 Matrivax Res & Dev Corp composição imunogênica, seu método de fabricação, método de fabricação de uma composição de vacina de matriz de proteína, e uso
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
PT2575870T (pt) 2010-06-04 2017-02-10 Wyeth Llc Formulações de vacinas
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
WO2012167088A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
EP2872535A1 (en) * 2012-07-16 2015-05-20 Pfizer Inc. Saccharides and uses thereof
SI2885007T1 (sl) 2012-08-16 2018-12-31 Pfizer Inc. Postopki in kompozicije glikokonjugacij
CN103656631B (zh) * 2012-09-24 2015-08-19 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法
GB201218660D0 (en) * 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
EP3363806B1 (en) 2012-12-20 2022-11-16 Pfizer Inc. Glycoconjugation process
ITMI20130142A1 (it) 2013-01-31 2014-08-01 Biosynth Srl Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati
US20150079132A1 (en) 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
BR112016016580B1 (pt) 2014-01-21 2024-01-09 Pfizer Inc Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
CN120718167A (zh) 2014-01-21 2025-09-30 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
IL312327B2 (en) * 2014-01-21 2026-02-01 Pfizer Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
EP3104886B1 (en) * 2014-02-14 2018-10-17 Pfizer Inc Immunogenic glycoprotein conjugates
GB201406569D0 (en) 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
CN104069504B (zh) * 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
US20150344530A1 (en) 2014-05-29 2015-12-03 Subhash V. Kapre Synthetic Peptides as Carriers for Conjugation with Polysaccharides
BR112017006447A2 (pt) 2014-10-09 2017-12-12 Msd Wellcome Trust Hilleman Laboratories Pvt Ltd processo de conjugação e conjugados sintéticos de oligossacarídeo-proteína obtidos dos mesmos
WO2016207905A2 (en) * 2015-06-23 2016-12-29 Biological E Limited Multivalent pneumococcal conjugate vaccine
CN108367063A (zh) 2015-07-21 2018-08-03 辉瑞公司 包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
JP6884145B2 (ja) * 2015-11-20 2021-06-09 ファイザー・インク 肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
MX2019014829A (es) 2017-06-10 2020-08-17 Inventprise Llc Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090317412A1 (en) * 2004-06-04 2009-12-24 Alexander Jeffery L Induction of an immune response against streptococcus pneumoniae polyaccharides
US20080260773A1 (en) * 2004-12-24 2008-10-23 Giuseppe Del Giudice Saccharide Conjugate Vaccines

Also Published As

Publication number Publication date
AU2018280272C1 (en) 2021-05-06
JP7132954B2 (ja) 2022-09-07
MX2019014829A (es) 2020-08-17
KR20240018698A (ko) 2024-02-13
KR20240018697A (ko) 2024-02-13
US20180353591A1 (en) 2018-12-13
AU2018280272B2 (en) 2021-01-28
MX2023009362A (es) 2023-08-16
ZA201908528B (en) 2020-09-30
CA3066911A1 (en) 2018-12-13
BR112019026192B1 (pt) 2022-05-10
CN111132691A (zh) 2020-05-08
EP3634481A4 (en) 2021-07-21
WO2018227177A1 (en) 2018-12-13
BR112019026192A2 (pt) 2020-06-30
AU2018280272A1 (en) 2020-01-30
CN118356485A (zh) 2024-07-19
EP3634481A1 (en) 2020-04-15
KR20200014921A (ko) 2020-02-11
MY198400A (en) 2023-08-28
JP2020523323A (ja) 2020-08-06
CA3066911C (en) 2022-05-24
US10688170B2 (en) 2020-06-23

Similar Documents

Publication Publication Date Title
KR102634811B1 (ko) 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신
US12251438B2 (en) Immunogenic compositions of polysaccharide-protein pegylated compounds
JP6808658B2 (ja) 多価肺炎球菌コンジュゲートワクチン
RU2634405C2 (ru) Иммуногенная композиция
CZ285650B6 (cs) Způsob přípravy kovalentního konjugátu oligosacharidu a nosičového proteinu
US12053515B2 (en) Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24F
AU2021207701A1 (en) Multivalent Streptococcus vaccines
US20250195640A1 (en) Immunogenic Compositions of Polysaccharide-Protein Pegylated Compounds
KR20200005458A (ko) 다가 폐렴구균 다당체-단백질 접합체를 포함하는 면역원성 조성물, 및 이를 포함하는 약학 조성물
WO2026064646A1 (en) Immunogenic compositions of pegylated polysaccharide compounds
HK40074022B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40021072B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200110

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210114

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230524

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240110

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240202

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240202

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240202

End annual number: 3

Start annual number: 1

PG1601 Publication of registration